Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The classic description of polycystic ovary syndrome (PCOS) is that it is a disorder
characterized by menstrual irregularity, chronic anovulation, androgen excess, and abnormal
gonadotropin secretion. Use of combined oral contraceptives (OCs) in women with PCOS
effectively reduces circulating androgens. Although OCs are the most common and one of the
oldest symptomatic treatment modalities for androgenic skin symptoms and for irregular
menstrual cycles caused by hyperandrogenism, the data concerning the effect of treatment of
PCOS women with different body mass index (BMI) are limited. This study is being done to
compare the hormone and metabolic changes after treatment with low-dose oral birth control
regimen of DRSP 3 mg/EE 0.02mg/levomefolate calcium 0.451 mg (Beyaz™) in women with PCOS with
different body weights.